Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $6.1M in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 10% Owner | Mar 31 '26 | Proposed Sale | $8.00 | 8,798 | $70,384 | — | Mar 31 05:00 PM |
Company profile
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Federated Hermes Kaufmann Smal | 10% Owner | Mar 31 '26 | Proposed Sale | $8.00 | 19,838 | $158,704 | — | Mar 31 04:57 PM |
| Federated Hermes Kaufmann Fund | 10% Owner | Mar 31 '26 | Proposed Sale | $8.00 | 31,808 | $254,464 | — | Mar 31 04:57 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.